- Home
- WST vs EQR Comparison
WST vs EQR Comparison
Compare WST & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WST | EQR |
|---|---|---|
| Founded | 1923 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 22.5B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | WST | EQR |
|---|---|---|
| Price | $277.45 | $62.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $346.78 | $70.00 |
| AVG Volume (30 Days) | 726.1K | ★ 2.2M |
| Earning Date | 02-12-2026 | 02-02-2026 |
| Dividend Yield | 0.32% | ★ 4.45% |
| EPS Growth | 0.17 | ★ 24.49 |
| EPS | ★ 6.75 | 3.03 |
| Revenue | $3,017,900,000.00 | ★ $3,078,827,000.00 |
| Revenue This Year | $7.01 | $5.06 |
| Revenue Next Year | $6.20 | $3.55 |
| P/E Ratio | $40.72 | ★ $20.53 |
| Revenue Growth | ★ 4.92 | 4.69 |
| 52 Week Low | $187.43 | $58.38 |
| 52 Week High | $348.90 | $75.86 |
Technical Indicators
Market Signals| Indicator | WST | EQR |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 59.12 |
| Support Level | $264.92 | $60.89 |
| Resistance Level | $278.43 | $62.52 |
| Average True Range (ATR) | 7.12 | 1.00 |
| MACD | 0.39 | 0.16 |
| Stochastic Oscillator | 58.89 | 87.45 |
Price Performance
Historical ComparisonAbout WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.